Ghost Tree Capital’s Reata Pharmaceuticals, Inc. Class A Common Stock RETA Stock Holding History

Ghost Tree Capital’s Portfolio RETA Stock Details RETA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-85,000	Closed	-$8.67M	–	84
2023 Q2	$8.67M	Buy	85,000 +15,000	+21%	+$1.42M	2.86%	13
2023 Q1	$6.36M	Sell	70,000 -430,000	-86%	-$25.2M	1.88%	21
2022 Q4	$19M	Sell	500,000 -225,000	-31%	-$7.74M	8.11%	1
2022 Q3	$18.2M	Buy	+725,000	New	+$20.1M	5.11%	4
2022 Q1	–	Sell	-55,000	Closed	-$1.45M	–	51
2021 Q4	$1.45M	Buy	+55,000	New	+$4.26M	0.52%	43
2020 Q4	–	Sell	-30,000	Closed	-$2.92M	–	57
2020 Q3	$2.92M	Sell	30,000 -20,000	-40%	-$2.5M	0.84%	33
2020 Q2	$7.8M	Hold	50,000	–	–	2.06%	22
2020 Q1	$7.22M	Sell	50,000 -25,000	-33%	-$4.83M	1.91%	16
2019 Q4	$15.3M	Buy	75,000 +25,000	+50%	+$4.56M	2.92%	9
2019 Q3	$4.01M	Buy	+50,000	New	+$4.24M	1.02%	32

Other funds holding RETA

DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return

IFP Advisors Tampa, Florida $4.82B AUM 20.19% 1-Year Est. Return

Ghost Tree Capital's RETA Position: Q3 2023 in Review

Ghost Tree Capital sold out of Reata Pharmaceuticals, Inc. Class A Common Stock (RETA) in Q3 2023, closing a stake of 85,000 shares — an estimated $8.67M sold.

Ghost Tree Capital first reported a position in RETA in Q3 2019 and held it in 10 quarters. The position peaked at $19M in Q4 2022. 2 funds tracked by Wall St. Rank hold RETA as of Q3 2023.

Ghost Tree Capital reported no remaining Reata Pharmaceuticals, Inc. Class A Common Stock position as of Q3 2023 after selling out during the quarter.
Ghost Tree Capital sold 85,000 Reata Pharmaceuticals, Inc. Class A Common Stock shares in Q3 2023, an estimated $8.67M.
Ghost Tree Capital first reported a position in Reata Pharmaceuticals, Inc. Class A Common Stock in Q3 2019 and held it in 10 quarters.
Ghost Tree Capital's Reata Pharmaceuticals, Inc. Class A Common Stock position peaked at $19M in Q4 2022.
2 funds tracked by Wall St. Rank held Reata Pharmaceuticals, Inc. Class A Common Stock as of Q3 2023.

Based on Ghost Tree Capital's 13F filing for Q3 2023, filed 14 Nov 2023.